Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alfacyte
- Development stage
- Unknown
- Lead developer
- ILC Therapeutics
- Modality
- Interferons → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Inhalation
01
Overview
Alfacyte is a novel, synthetic hybrid interferon developed by ILC Therapeutics as a broad-spectrum antiviral treatment. It is designed as an inhaled medicine to treat respiratory viral infections (RVIs), including SARS-CoV-2 (COVID-19) and Respiratory Syncytial Virus (RSV). The drug is an engineered protein that combines properties of different interferon subtypes to enhance potency and reduce side effects compared to naturally occurring interferons. Preclinical studies at the University of St Andrews demonstrated high potency against SARS-CoV-2 in vitro. The development program includes manufacturing scale-up with 3P Bio SA and clinical trial preparation with TCRS.
- Brand names
- Alfacyte
- Other names
- Alfacytehybrid interferonsynthetic hybrid interferon
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on Alfacyte.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alfacyte.